Company: DAWN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0000950170-25-026654
Chunk: 37

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 16
Chunk 37
---
 obligation payment

        8,100

        —

        Intangible assets, gross

        17,100

        —

        Less accumulated amortization

        (1,470
        )

        —

        Intangible assets, net
         
        $
        15,630

        $
        —

      The Company incurred amortization expense of $1.5 million for the year ended December 31, 2024.

F-22

The estimated aggregate amortization expense for amortizable finite-lived intangible assets as of December 31, 2024 is as follows:

        Year Ending December 31,
        EstimatedAmortizationExpense

        2025
        $
        2,345

        2026
         
        2,345

        2027
         
        2,345

        2028
         
        2,345

        2029
         
        2,345

        Thereafter
         
        3,905

        Total future expected amortization expense
        $
        15,630

6. Significant AgreementsTakeda asset purchase agreement On December 16, 2019, a subsidiary of the Company entered into an asset purchase agreement, or the Takeda Asset Agreement, with Millennium Pharmaceuticals, Inc., a related party and an affiliate of Takeda Pharmaceutical Company Limited, or Takeda. Effective December 31, 2021, the subsidiary was merged with and into the Company, with the Company being the surviving corporation and assuming the subsidiary’s obligations under the Takeda Asset Agreement. Pursuant to the Takeda Asset Agreement, the Company purchased certain technology rights and know-how related to TAK-580 (which is now OJEMDA™ (tovorafenib)) that provides a new approach for treating patients with primary brain tumors or brain metastases of solid tumors. The Company also received clinical inventory supplies to use in the Company's research and development activities of such RAF-inhibitor and an assigned investigator clinical trial agreement. Takeda also assigned to the Company its exclusive license agreement, or the Viracta License Agreement, with Viracta. Takeda also granted the Company a worldwide, sublicensable exclusive license under specified patents and know-how and non-exclusive license under other patents and know-how generated by Takeda under the Takeda Asset Agreement. The Company also granted Takeda a grant back license, as defined in the Takeda